[go: up one dir, main page]

AR055165A1 - Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c. - Google Patents

Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c.

Info

Publication number
AR055165A1
AR055165A1 ARP060103983A ARP060103983A AR055165A1 AR 055165 A1 AR055165 A1 AR 055165A1 AR P060103983 A ARP060103983 A AR P060103983A AR P060103983 A ARP060103983 A AR P060103983A AR 055165 A1 AR055165 A1 AR 055165A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
amino
alkoxy
co2r6
Prior art date
Application number
ARP060103983A
Other languages
English (en)
Inventor
John A Bender
Robert G Gentles
Piyasena Hewawasam
Thomas W Hudyma
John F Kadow
Scott W Martin
Alicia Regueiro-Ren
Kap-Sun Yeung
Yong Tu
Katherine A Grant-Young
Xiaofan Zheng
Carl P Bergstrom
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR055165A1 publication Critical patent/AR055165A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos y sales de las formulas (1), (2), (3) y (4) así como composiciones y métodos para usar los compuestos. Los compuestos tienen actividad contra el virus de la hepatitis C (VHC) y son utiles en el tratamiento de aquellos infectados con VHC. Reivindicacion 1: Un compuesto de la formula (1) en donde R1 es CO2R6 o CONR7R8; R2 es CONR9R10, CO2bencilo, NHCO2(alquilo), NHCO2bencilo, NHCO(alquilo), NHCO(cicloalquilo), NHCOR14, NHCO((R15)alquilo), NHCO((R16)alquil0), NHCO(tetrahidropiranilo, NHCO(metoxicicloalquilo), NHCON(R6)2, NHCON(R6)((N(R6)2)alquilo), NHCON(R6)((CO2R6)alquilo), NHCON(R6)((CON(R6)2)alquilo, NHCON(R6) ((COR15)alquilo, NHCON(R6)((tetrahidropiranil)alquilo), o como se muestra en las formulas (5); R3 es H o alquilo; R4 es H, halo, alquilo, alcoxi o benciloxi; R5 es cicloalquilo C5-7; R6 es H, alquilo o cicloalquilo; R7 es H, alquilo, cicloalquilo, alcoxi aminoalquilo, (alquilamino)alquilo, (dialquilamino)alquilo, (CO2R6)alquilo, (CON(R6) (R6))alquilo, (alquilo)CONH, tetrazolilo, tetrahidropiranilo, sulfolanilo, SO2R11, SO2R12, o (R13)alquilo; R8 es hidrogeno, alquilo, o cicloalquilo; o NR7R8 tomado junto es pirrolidinilo, piperidinilo, piperazinilo, piperazinilo, homomorfolinilo, homopiperidinilo, morfolinilo, o tiomorfolinilo, y es substituido con 0-2 substituyentes seleccionados de halo, alquilo, y haloalquilo; R9 es cicloalquilo, dihidroxialquilo, (alcoxi)alquilo, (R12)alquilo, (CHO)alquilo, (CO2R6)alquilo, (CON(R6)2)alquilo, (COR12) alquilo, (COR15) alquilo, ((alcoxialquilo)amido)alquilo, (alquilamido)alquilo, (tetrahidrofuranilo)alquilo, (dioxolanil)alquilo, (alquiloCO)(R6)amino, ((alquiloCO)(R6)amino)alquilo, tetrahidropiranilo, o sulfolanilo; R10 es hidrogeno, alquilo, cicloalquilo, hidroxialquilo, dihidroxialquilo, (alcoxi) alquilo, aminoalquilo, (alquilamino)alquilo, (dialquilamino)alquilo, (R12)alquilo, (CHO)alquilo, (CO2R6)alquilo, (CON(R6)2)alquilo, (COR12)alquilo, (COR15)alquilo, (R16)alquilo, ((alcoxialquilo)amido)alquilo, (alquilamido)alquilo, (tetrahidrofuranilo)alquilo, (dioxolanilo)alquilo, (alquiloCO)(R6) amino, ((alquiloCO(R6)amino)alquilo, tetrahidropiranilo, o sulfalanilo; o NR9R10 tomado junto es azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, homomorfolinilo, homopiperidinilo, morfolinilo, o tiomorfolinilo, y es substituido con 0-4 substituyentes seleccionados del grupo que consiste de halo, hidroxi, OPO(OR6)2, alcoxi, alquilo, cicloalquilo, (cicloalquilo)alquilo, haloalquilo, hidroxialquilo, alcoxialquilo, (hidroxi) alcoxialquilo, (alcoxi)alquilo, amino, alquilamino, dialquilamino, (alquiloCO)(R6)amino, (alcoxiCO)(R6)amino, (alcoxialquiloCO)(R6)amino, (alquiloCO)alquiloamino, (cicloalquilo)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alquenilo), (R12)CO, (alquilo)CO, (cicloalquilo)CO, (hidroxialquilo)CO, (hidroxi)cicloalquilo)CO, (aminoalquilo)CO, (acetoxialquilo)CO, PhCO, (furanilo)CO, (benzodioxanil)CO, (alquilo)CO2, SO2R11, SO2R12, (CO2R6)alquilo, (CON(R6)2)alquilo, (COR12)alquilo, (alquiloCO)(R6)aminoalquilo, (PhCONH)alquilo, (R12)alquilo, R12, fenilo, metoxifenilo, pirrolilo, furanilo, tienilo, imidazolilo, isoxazolilo, oxazolilo, tiazolilo, triazolilo, oxadiazolilo, piridinilo, pirimidinilo, pirazinilo, triazinilo, pirazolilo, o como se muestra en as formulas (6) con la condicion de que si NR9R10 es pirrolidinilo, piperidinilo, piperazinilo, homomorfolinilo, homopiperidinilo, morfolinilo, o tiomorfolinilo puede substituirse con 0-2 substituyentes seleccionados de alquilo, hidroxi, amino, alquilamino, dialquilamino, pirrolidinilo, piperidinilo o piridinilo; o NR9R10 tomado junto es como se muestra en las formulas (7) o NR9R10 tomado junto es un amina bicíclica punteada [2.2.1] o [2.2.2] en donde el biciclo contiene 0-1 NR6, NCO2R6, u O; R11es alquilo, haloalquilo, cicloalquilo, alcoxi, amino, alquilamino, dialquilamino, ((R6)(R6)N)alquilamino, (((R6)(R6)N)alquilo)2amino, N,O- dimetilhidroxilamino, o fenilo, en donde el fenilo es substituido con 0-2 substituyentes seleccionados del grupo que consiste de halo, alquilo, haloalquilo y alcoxi; R12 es pirrolidinilo, piperidinilo, piperazinilo, homomorfolinilo, homopiperidinilo, morfolinilo, o tiomorfolinilo, y es substituido con 0-2 substituyentes seleccionados de halo, alquilo, haloalquilo y alcoxi; R13 es pirrolidinilo, piperidinilo, piperazinilo, homomorfolinilo, homopiperidinilo, morfolinilo, tiomorfolinilo, tetrahidrofuranilo, furanilo, tienilo, pirrolilo, pirazolilo, imidazolilo, isoxazolilo, oxazolilo, triazolilo, oxadiazolilo, tetrazolilo, piridinilo, pirazinilo, pirimidinilo, imidazopiridinilo, o benzimidazol y es substituido con 0- 2 substituyentes alquilo; R14 es azetidina, pirrolidinilo, piperidinilo, piperazinilo, piperazinilo, homomorfolinilo, homopiperidinilo, morfolinilo, tiomorfolinilo, o S,S- dioxotiomorfolinilo, y es substituido con 0-3 substituyentes seleccionados de halo, alquilo, hidroxi, alcoxi, aminoalquilo, (alquilamino)alquilo, (dialquilamino)alquilo, (CO2R6)alquilo, (CON(R6)2)alquilo, ((R6CO)(R6)amino)alquilo, (R15)alquilo, (R6CO)(R6)amino, R15, alquiloCO, CF3CO, CO2R6, CON(R6)2, o SO2R6 o R14 es una amina bicíclica ponteada [2.2.1) o [2.2.2] en donde el biciclo contiene 0-1 O; R15 es azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, homomorfolinilo, homopiperidinilo, morfolinilo, o tiomorfolinilo, y es substituido con 0-2 substituyentes halo, alquilo, o alcoxi; y la línea de rayas es ya sea un enlace sencillo o un enlace doble, con la condicion de que si la línea de rayas es un enlace sencillo, el carbono que porta el asterisco está en la configuracion ya sea R, la configuracion S, o una mezcla de R y S; o una sal farmacéuticamente aceptable del mismo.
ARP060103983A 2005-09-13 2006-09-12 Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c. AR055165A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71669305P 2005-09-13 2005-09-13
US77150106P 2006-02-08 2006-02-08

Publications (1)

Publication Number Publication Date
AR055165A1 true AR055165A1 (es) 2007-08-08

Family

ID=37637507

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103983A AR055165A1 (es) 2005-09-13 2006-09-12 Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c.

Country Status (5)

Country Link
US (1) US7473688B2 (es)
AR (1) AR055165A1 (es)
PE (1) PE20070839A1 (es)
TW (1) TW200745120A (es)
WO (1) WO2007033175A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7795247B2 (en) 2004-10-26 2010-09-14 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetracyclic indole derivatives as antiviral agents
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007041632A2 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140254A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
AU2008277440A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
PT2209789E (pt) * 2007-11-20 2012-01-16 Bristol Myers Squibb Co Inibidores de ns5b de vhc de indolbenzazepina condensados com ciclopropilo
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
NZ585370A (en) 2007-12-19 2012-09-28 Boehringer Ingelheim Int Viral polymerase inhibitors
BRPI0908021A2 (pt) * 2008-02-04 2015-07-21 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
US8119628B2 (en) * 2008-03-27 2012-02-21 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine HCV NS5B inhibitors
CN101977914A (zh) * 2008-03-27 2011-02-16 百时美施贵宝公司 用于治疗丙型肝炎的化合物
ATE531373T1 (de) 2008-03-27 2011-11-15 Bristol Myers Squibb Co Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
MX2010010245A (es) * 2008-03-27 2010-10-05 Bristol Myers Squibb Co Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona.
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2280989B1 (en) * 2008-06-06 2016-02-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
CN102271699A (zh) 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv和hiv感染的环孢菌素衍生物
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
EP2396329B1 (en) * 2009-02-11 2014-10-29 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
PE20140039A1 (es) 2010-12-30 2014-03-01 Enanta Pharm Inc Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
HUE045701T2 (hu) 2013-03-13 2020-01-28 Forma Therapeutics Inc 2-Hidroxi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etán-1-on származékok és rokon vegyületek mint zsírsav szintáz (FASN) inhibitorok, rák kezelésére
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400963A (en) * 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
ES2322602T3 (es) 2004-02-24 2009-06-23 Japan Tobacco, Inc. Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc.
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) * 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7662809B2 (en) 2004-10-26 2010-02-16 Istituto Di Richerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds

Also Published As

Publication number Publication date
WO2007033175A1 (en) 2007-03-22
PE20070839A1 (es) 2007-09-10
TW200745120A (en) 2007-12-16
US20070078122A1 (en) 2007-04-05
US7473688B2 (en) 2009-01-06

Similar Documents

Publication Publication Date Title
AR055165A1 (es) Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c.
AR061053A1 (es) Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
AR081495A1 (es) Compuestos para el tratamiento de la hepatitis c
AR049124A1 (es) Compuestos de de pirimidinona como inhibidores de la integrasa del virus hiv, composiciones farmaceuticas que las contienen y su uso en el tratamiento del sida y de la infeccion por hiv
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
TNSN07471A1 (en) Novel 2,4 - dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
AR073586A1 (es) Compuestos heterociclicos utiles para el tratamiento de vhc
CO6140059A2 (es) Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3)
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR045180A1 (es) Derivados 3-amino cromado y 2-amino tetralina y composiciones que contienen a dichos compuestos
AR083070A1 (es) Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
PA8651001A1 (es) Compuestos quimicos
AR067897A1 (es) Compuestos para el tratamiento de hepatitis c
DK1585493T3 (da) Triazinderivater som UV-absorbenter
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
TNSN06203A1 (en) Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
PE20050311A1 (es) 4-feniltetrahidroisoquinoleinas sustituidas, procedimiento para prepararlas, y el medicamento que las comprende
AR071684A1 (es) Compuestos para el tratamiento de la hepatitis c
AR054417A1 (es) Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure